Sign up to save your podcasts
Or
Share Neoadjuvant Immunotherapy and Radiation Boosts Response in NSCLC
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Neoadjuvant Immunotherapy and Radiation Boosts Response in NSCLC
Guest: Nasser Altorki, M.D.
Nasser Altorki, MD, chief of thoracic surgery at NewYork-Presbyterian and Weill Cornell Medicine, shares the results of a first-of-its-kind study evaluating low-dose radiation combined with immunotherapy for neoadjuvant treatment of non-small cell lung cancer (NSCLC) tumors. The dual-therapy treatment of durvalumab in combination with stereotactic body radiation was almost twice as effective at tumor killing compared to durvalumab alone.
© 2025 NewYork-Presbyterian
View all episodes
By ReachMDGuest: Nasser Altorki, M.D.
Nasser Altorki, MD, chief of thoracic surgery at NewYork-Presbyterian and Weill Cornell Medicine, shares the results of a first-of-its-kind study evaluating low-dose radiation combined with immunotherapy for neoadjuvant treatment of non-small cell lung cancer (NSCLC) tumors. The dual-therapy treatment of durvalumab in combination with stereotactic body radiation was almost twice as effective at tumor killing compared to durvalumab alone.
© 2025 NewYork-Presbyterian